Trials / Completed
CompletedNCT00203060
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 404 (actual)
- Sponsor
- Teva Neuroscience, Inc. · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline Mesylate | tablet, 1 or 2 mg, daily, 58 weeks |
| DRUG | placebo | tablet, once daily, 58 weeks |
Timeline
- Start date
- 1997-07-01
- Primary completion
- 2000-07-01
- Completion
- 2000-07-01
- First posted
- 2005-09-20
- Last updated
- 2011-04-12
Source: ClinicalTrials.gov record NCT00203060. Inclusion in this directory is not an endorsement.